Analysts think NCNA stock price could increase by 4046%
Jun 14, 2024, 6:29 AM
-6.67%
What does NCNA do
NuCana Plc, a clinical-stage biopharmaceutical company, specializes in enhancing cancer treatment outcomes using its ProTide technology, with drugs like NUC-3373 and NUC-7738 in various clinical trial phases. NUC-3373, a modified form of the anti-cancer agent 5-FU, is undergoing Phase Ib/II trials for advanced colorectal cancer, while NUC-7738, derived from 3’-deoxyadenosine, is in Phase I/II trials for advanced solid tumors.
4 analysts think NCNA stock price will increase by 4046.34%. The current median analyst target is $127.50 compared to a current stock price of $3.08. The lowest analysts target is $101.00 and the highest analyst target is $157.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
